NCT06927180View on ClinicalTrials.gov

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

May 1, 2029

Study Completion Date

December 1, 2030

Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
DRUG

SHR-A1811

an anti-HER2 antibody-drug conjugate (ADC)

DRUG

Pertuzumab

Pertuzumab

DRUG

Albumin-Paclitaxel

Nab paclitaxel

DRUG

Docetaxel

Docetaxel

DRUG

Carboplatin

Carboplatin

DRUG

Trastuzumab

Trastuzumab

Trial Locations (1)

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV